Nomination committee’s proposal to composition of the Board

The Nomination Committee of Meda AB proposes the election of Karen Sörensen as
new board member. The committee also proposes the re-election of Peter Claesson,
Peter von Ehrenheim, Marianne Hamilton, Tuve Johannesson, Anders Lönner and Lars
Westerberg as board members. Bert-Åke Eriksson is proposed to be re-appointed as
board chairman.

Karen Sörensen is currently CEO of Philips Nordic and responsible for Philips
Healthcare Nordic. She was previously Vice President of Sanofi-Aventis with
responsibility for western Europe. Söderberg has experience from several global
pharmaceutical-, biotechnology- and medical technology companies. She holds a
Master of Science and an MBA from INSEAD.

The nomination committee for the AGM 2013 consists of Evert Carlsson (Swedbank
Robur Funds), Bengt Belfrage (Nordeas Funds), Anders Oscarsson (AMF Funds), Bert
-Åke Eriksson (Meda’s chairman of the board) and Karl-Magnus Sjölin (Stena
Sessan).

The nomination committee's other proposals concerning the chairman of the
meeting, remuneration and the method used to appoint the nomination committee
will be disclosed on the website and in the notice of the Annual General
Meeting.

The Annual General Meeting of Meda AB will be held on May 7, 2013 at 17.00 CET
at Meda AB, Pipers väg 2A, Solna.


For further inquiries, please contact:

Anders Larnholt, Vice President Corporate Development & IR      ph: +46 709
-458 878

Karl-Magnus Sjölin, Chairman of the Nomination Committee        ph: +46 31-774
35 35


MEDA AB (publ) is a leading international specialty pharma company. Meda’s
products are sold in 120 countries worldwide and the company is represented by
its own organizations in 50 countries. The Meda share is listed under
Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more,
visit www.meda.se.

Forward-looking statements
This press release is not an offer to sell or a solicitation to buy shares in
Meda. This press release also contains certain forward-looking statements with
respect to certain future events and Meda’s potential financial performance.
These forward-looking statements can be identified by the fact that they do not
relate only to historical or current facts, and may sometimes include words such
as “may”, “will”, “seek”, “anticipate”, “expect”, “estimate”, “intend”, “plan”,
“forecast”, “believe” or other words of similar meaning. These forward looking
statements reflect the current expectations on future events of the management
at the time such statements are made, but are made subject to a number of risks
and uncertainties. In the event such risks or uncertainties materialize, Meda’s
results could be materially affected. The risks and uncertainties include, but
are not limited to, risks associated with the inherent uncertainty of
pharmaceutical research and product development, manufacturing and
commercialization, the impact of competitive products, patents, legal
challenges, government regulation and approval, Meda’s ability to secure new
products for commercialization and/or development and other risks and
uncertainties detailed from time to time in Meda AB’s interim or annual reports,
prospectuses or press releases. Listeners and readers are cautioned that no
forward-looking statement is a guarantee of future performance and that actual
result could differ materially from those contained in the forward-looking
statements. Meda does not intend, nor undertakes, to update any such forward
looking statements.